Biotechnological and biomedical applications of mesenchymal stem cells as a therapeutic system

References

• Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. 2008. Immunomodulation by mesenchymal stem cells a potential therapeutic strategy for type 1 diabetes. Diabetes. 57:1759–1767.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger MF. 2005. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 105:1815–1822.
   PubMed Web of Science ®Google Scholar
• Akbari A, Mozdarani H, Akhlaghpoor S, Pourfatollah A, Soleimani M. 2007. Evaluation of the homing of human CD34 + cells in mouse bone marrow using clinical MR imaging. Pak J Biol Sci. 10: 833–842.
   PubMedGoogle Scholar
• Angoulvant D, Clerc A, Benchalal S, Galambrun C, Farre A, Bertrand Y, Eljaafari A 2004. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology. 41:469–476.
   PubMed Web of Science ®Google Scholar
• Arikawa T, Omura K, Morita I 2004. Regulation of bone morphogenetic protein 2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol. 200:400–406.
   PubMed Web of Science ®Google Scholar
• Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G 2005. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. 35:1482–1490.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature. 392:245–252.
   PubMed Web of Science ®Google Scholar
• Barry F, Boynton R, Murphy M, Zaia J. 2001. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Commun. 289: 519–524.
   PubMed Web of Science ®Google Scholar
• Ben-Ami E, Berrih-Aknin S, Miller A. 2011. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev. 10:410–415.
   PubMed Web of Science ®Google Scholar
• Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, et al 2005. Human mesenchymal stem cells alter antigen-presenting cell maturation, induce T-cell unresponsiveness. Blood. 105: 2214–2219.
   PubMed Web of Science ®Google Scholar
• Bingisser RM, Tilbrook PA, Holt PG, Kees UR 1998. Macrophage- derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol. 160: 5729–5734.
   PubMed Web of Science ®Google Scholar
• Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, et al. 2007. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 110:1362–1369.
   PubMed Web of Science ®Google Scholar
• Bruder SP, Ricalton NS, Boynton RE, Connolly TJ, Jaiswal N, Zaia J, Barry FP. 1998. Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Miner Res. 13:655–663.
   PubMed Web of Science ®Google Scholar
• Bühring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W. 2007. Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci. 1106:262–271.
   PubMed Web of Science ®Google Scholar
• Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM 2001. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, bone marrow. Blood. 98:2396–2402.
   PubMed Web of Science ®Google Scholar
• Caplan AI, Dennis JE 2006. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 98:1076–1084.
   PubMed Web of Science ®Google Scholar
• Chamberlain G, Fox J, Ashton B, Middleton J. 2007. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 25:2739–2749.
   PubMed Web of Science ®Google Scholar
• Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. 2006. Human mesenchymal stem cells modulate B-cell functions. Blood. 107:367–372.
   PubMed Web of Science ®Google Scholar
• Dazzi F, Marelli Berg FM 2008. Mesenchymal stem cells for graft versus host disease: Close encounters with T cells. Eur J Immunol. 38:1479–1482.
   PubMed Web of Science ®Google Scholar
• Deans RJ, Moseley AB. 2000. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 28:875–884.
   PubMed Web of Science ®Google Scholar
• Delalat B, Pourfathollah AA, Soleimani M, Mozdarani H, Ghaemi SR, Movassaghpour AA, Kaviani S 2009. Isolation, ex vivo expansion of human umbilical cord blood-derived CD34 + stem cells, their cotransplantation with or without mesenchymal stem cells. Hematology. 14:125–132.
   PubMed Web of Science ®Google Scholar
• Deng W, Han Q, Liao L, You S, Deng H, Zhao RC 2005. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T, B lymphocytes from BXSB mice. DNA Cell Biol. 24:458–463.
   PubMed Web of Science ®Google Scholar
• Devine MJ, Mierisch CM, Jang E, Anderson PC, Balian G. 2002. Transplanted bone marrow cells localize to fracture callus in a mouse model. J Orthop Res. 20:1232–1239.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 99:3838–3843.
   PubMed Web of Science ®Google Scholar
• Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ 2009. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and-9. Diabetes. 58:1797–1806.
   PubMed Web of Science ®Google Scholar
• Djouad F, Charbonnier LM, Bouffi C, Louis Plence P, Bony C, Apparailly F, et al 2007. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin 6 dependent mechanism. Stem cells. 25:2025–2032.
   PubMed Web of Science ®Google Scholar
• Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. 2003. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 102:3837–3844.
   PubMed Web of Science ®Google Scholar
• Du Z, Wei C, Cheng K, Han B, Yan J, Zhang M, et al. 2013. Mesenchymal stem cell–conditioned medium reduces liver injury, enhances regeneration in reduced-size rat liver transplantation. J Surg Res. 183:907–915.
   PubMed Web of Science ®Google Scholar
• English K, Barry FP, Field-Corbett CP, Mahon BP 2007. IFN-γ and TNF-α differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett. 110:91–100.
   PubMed Web of Science ®Google Scholar
• Fedyk ER, Jones D, Critchley HO, Phipps RP, Blieden TM, Springer TA 2001. Expression of stromal-derived factor-1 is decreased by IL-1, TNF, in dermal wound healing. J Immunol. 166:5749–5754.
   PubMed Web of Science ®Google Scholar
• Fickert S, Fiedler J, Brenner RE. 2004. Identification of subpopulations with characteristics of mesenchymal progenitor cells from human osteoarthritic cartilage using triple staining for cell surface markers. Arthritis Res Ther. 6:R422–R432.
   PubMed Web of Science ®Google Scholar
• Gebler A, Zabel O, Seliger B. 2012. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med.18:128–134.
   PubMed Web of Science ®Google Scholar
• Gerdoni E, Gallo B, Casazza S, Musio S, Bonanni I, Pedemonte E, et al. 2007. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol. 61:219–227.
   PubMed Web of Science ®Google Scholar
• Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noël D. 2010a. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther. 1:2.
   PubMed Web of Science ®Google Scholar
• Ghannam S, Pène J, Torcy-Moquet G, Jorgensen C, Yssel H 2010b. Mesenchymal stem cells inhibit human Th17 cell differentiation, function, induce a T regulatory cell phenotype. J Immunol. 185: 302–312.
   PubMed Web of Science ®Google Scholar
• Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F 2005. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 105:2821–2827.
   PubMed Web of Science ®Google Scholar
• Gonen-Gross T, Goldman-Wohl D, Huppertz B, Lankry D, Greenfield C, Natanson-Yaron S, et al. 2010. Inhibitory NK receptor recognition of HLA-G: regulation by contact residues and by cell specific expression at the fetal-maternal interface. PLoS One. 5:e8941.
   PubMed Web of Science ®Google Scholar
• González MA, Gonzalez Rey E, Rico L, Büscher D, Delgado M 2009. Treatment of experimental arthritis by inducing immune tolerance with human adipose derived mesenchymal stem cells. Arthritis Rheum. 60:1006–1019.
   PubMed Web of Science ®Google Scholar
• Groh ME, Maitra B, Szekely E, Koç ON 2005. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol. 33:928–934.
   PubMed Web of Science ®Google Scholar
• Gronthos S, Graves S, Ohta S, Simmons P. 1994. The STRO-1 + fraction of adult human bone marrow contains the osteogenic precursors. Blood84:4164–4173.
   PubMed Web of Science ®Google Scholar
• Groth CG, Ringdén O. 1984. Transplantation in relation to the treatment of inherited disease. Transplantation. 38:319–326.
   PubMed Web of Science ®Google Scholar
• Hirata Y, Sugita T, Gyo K, Yanagihara N 1993. Experimental vestibular neuritis induced by herpes simplex virus. Acta Otolaryngol Suppl. 113:79–81.
   Google Scholar
• Hirohata S, Kikuchi H 2003. Behcet's disease. Arthritis Res Ther. 5: 139–146.
   PubMed Web of Science ®Google Scholar
• Hoogduijn MJ, Popp F, Verbeek R, Masoodi M, Nicolaou A, Baan C, Dahlke M-H 2010. The immunomodulatory properties of mesenchymal stem cells, their use for immunotherapy. Int Immunopharmacol. 10:1496–1500.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. 2002. Isolated allogeneic bone marrow-derived mesenchymal cells engraft, stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A. 99:8932–8937.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Maziarz RT, Kebriaei P 2011. MSCs in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 17:S21–S29.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. 1999. Transplantability, therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 5:309–313.
   PubMed Web of Science ®Google Scholar
• Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, et al. 2001. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 97:1227–1231.
   PubMed Web of Science ®Google Scholar
• Imhof BA, Aurrand-Lions M 2004. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol. 4:432–444.
   PubMed Web of Science ®Google Scholar
• Ivanova-Todorova E, Bochev I, Mourdjeva M, Dimitrov R, Bukarev D, Kyurkchiev S, et al. 2009. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett. 126:37–42.
   PubMed Web of Science ®Google Scholar
• Jiang X-X, Zhang Y, Liu B, Zhang S-X, Wu Y, Yu X-D, Mao N. 2005. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood. 105: 4120–4126.
   PubMed Web of Science ®Google Scholar
• Jorgensen C, Gordeladze J, Noel D. 2004. Tissue engineering through autologous mesenchymal stem cells. Curr Opin Biotechnol. 15:406–410.
   PubMed Web of Science ®Google Scholar
• Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG 2010. Etiopathogenesis of Behçet's disease with emphasison the role of immunological aberrations. Clin Rheumatol. 29:1211–1216.
   PubMed Web of Science ®Google Scholar
• Kim J, Hematti P. 2009. Mesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophages. Exp Hematol. 37:1445–1453.
   PubMed Web of Science ®Google Scholar
• Kitoh H, Kitakoji T, Tsuchiya H, Mitsuyama H, Nakamura H, Katoh M, Ishiguro N. 2004. Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis—a preliminary result of three cases. Bone. 35:892–898.
   PubMed Web of Science ®Google Scholar
• Kong Q-F, Sun B, Bai S-S, Zhai D-X, Wang G-Y, Liu Y-M, et al. 2009. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF. J Neuroimmunol. 207:83–91.
   PubMed Web of Science ®Google Scholar
• Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI, Lazarus HM 2000. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol. 18:307–307.
   PubMed Web of Science ®Google Scholar
• Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. 2006a. Role for interferon in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 24: 386–398.
   PubMed Web of Science ®Google Scholar
• Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F 2003. Bone marrow mesenchymal stem cells inhibit the response of naive, memory antigen-specific T cells to their cognate peptide. Blood. 101:3722–3729.
   PubMed Web of Science ®Google Scholar
• Krampera M, Pasini A, Pizzolo G, Cosmi L, Romagnani S, Annunziato F. 2006b. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol. 6:435–441.
   PubMed Web of Science ®Google Scholar
• Krivit W, Peters C, Shapiro EG. 1999. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol. 12:167–176.
   PubMed Web of Science ®Google Scholar
• Lazarus H, Haynesworth S, Gerson S, Rosenthal N, Caplan A 1995. Ex vivo expansion, subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 16: 557–564.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Götherström C, Seidel C, Sundberg B, Sundin M, et al. 2004a. Mesenchymal stem cells inhibit the expression of CD25 (interleukin 2 receptor), CD38 on phytohaemagglutinin activated lymphocytes. Scand J Immunol. 60:307–315.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O 2004b. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 363:439–1441.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Ringden O 2007. Immunomodulation by mesenchymal stem cells, clinical experience. J Intern Med. 262:509–525.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. 2003. HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 31: 890–896.
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Tammik L, Sundberg B, Haynesworth S, Ringden O 2003. Mesenchymal stem cells inhibit, stimulate mixed lymphocyte cultures, mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 57:11–20.
   PubMed Web of Science ®Google Scholar
• Lee JW, Gupta N, Serikov V, Matthay MA. 2009. Potential application of mesenchymal stem cells in acute lung injury. Expert Opin Biol Ther. 9:1259–1270.
   PubMed Web of Science ®Google Scholar
• Lee ST, Jang JH, Cheong JW, Kim JS, Maemg HY, Hahn JS, et al. 2002. Treatment of high risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co infusion of T cell depleted haematopoietic stem cells and culture expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol. 118:1128–1131.
   PubMed Web of Science ®Google Scholar
• Lim J-H, Kim J-S, Yoon I-H, Shin J-S, Nam H-Y, Yang S-H, et al. 2010. Immunomodulation of delayed-type hypersensitivity responses by mesenchymal stem cells is associated with bystander T cell apoptosis in the draining lymph node. J Immunol. 185: 4022–4029.
   PubMed Web of Science ®Google Scholar
• Liu J, Lu X, Wan L, Li Y, Li S, Zeng L, et al. 2004. Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbred-line. Transplant Proc. 36:3272–3275.
   PubMed Web of Science ®Google Scholar
• Lotfinegad P. 2014. Immunomodulatory nature and site specific affinity of mesenchymal stem cells: a hope in cell therapy. Adv Pharm Bull. 4:5.
   PubMedGoogle Scholar
• Luster AD, Alon R, von Andrian UH 2005. Immune cell migration in inflammation: present, future therapeutic targets. Nat Immunol. 6:1182–1190.
   PubMed Web of Science ®Google Scholar
• MacDonald GI, Augello A, De Bari C. 2011. Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases. Arthritis Rheum. 63:2547–2557.
   PubMed Web of Science ®Google Scholar
• Maccario R, Podestà M, Moretta A, Cometa A, Comoli P, Montagna D, et al. 2005. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4 + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 90:516–525.
   PubMed Web of Science ®Google Scholar
• Maitra B, Szekely E, Gjini K, Laughlin M, Dennis J, Haynesworth S, Koc O. 2004. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 33:597–604.
   PubMed Web of Science ®Google Scholar
• Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, McIntosh KR, Mosca JD. 2003. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci. 10:228–241.
   PubMed Web of Science ®Google Scholar
• Mazaheri T, Esmaeilzadeh A, Mirzaei MH 2012. Introducing the immunomodulatory effects of mesenchymal stem cells in an experimental model of Behçet's disease. J Med Hypotheses Ideas. 6:23–27.
   Google Scholar
• Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, et al. 1998. Impaired B-lymphopoiesis, myelopoiesis, derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. Proc Natl Acad Sci U S A. 95:9448–9453.
   PubMed Web of Science ®Google Scholar
• McTaggart SJ, Atkinson K 2007. Mesenchymal stem cells: Immunobiology, therapeutic potential in kidney disease (Review Article). Nephrology (Carlton). 12:44–52.
   PubMed Web of Science ®Google Scholar
• Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D 2004. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase–mediated tryptophan degradation. Blood. 103:4619–4621.
   PubMed Web of Science ®Google Scholar
• Mellman I, Steinman RM. 2001. Dendritic cells-specialized and regulated antigen processing machines. Cell. 106:255–258.
   PubMed Web of Science ®Google Scholar
• Mohammadian M, Shamsasenjan K. 2013. Mesenchymal stem cells: new aspect in cell-based regenerative therapy. Adv Pharm Bull. 3:433.
   PubMedGoogle Scholar
• Moriscot C, de Fraipont F, Richard MJ, Marchand M, Savatier P, Bosco D, et al. 2005. Human bone marrow mesenchymal stem cells can express insulin and key transcription factors of the endocrine pancreas developmental pathway upon genetic and/or microenvironmental manipulation in vitro. Stem Cells. 23:594–603.
   PubMed Web of Science ®Google Scholar
• Mueller SM, Glowacki J. 2001. Age related decline in the osteogenic potential of human bone marrow cells cultured in three dimensional collagen sponges. J Cell Biochem. 82:583–590.
   PubMed Web of Science ®Google Scholar
• Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 281:191–1193.
   Web of Science ®Google Scholar
• Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S, et al. 2006. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity. 24:801–812.
   PubMed Web of Science ®Google Scholar
• Nasef A, Zhang Y, Mazurier C, Bouchet S, Bensidhoum M, Francois S, et al. 2009. Selected Stro 1 enriched bone marrow stromal cells display a major suppressive effect on lymphocyte proliferation. Int J Lab Hematol. 31:9–19.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Fibbe WE 2007. Immunomodulatory properties of mesenchymal stromal cells. Blood. 110:3499–3506.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. 2006. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol. 177:2080–2087.
   PubMed Web of Science ®Google Scholar
• Otto W, Rao J. 2004. Tomorrow’s skeleton staff: mesenchymal stem cells and the repair of bone and cartilage. Cell Prolif. 37:97–110.
   PubMed Web of Science ®Google Scholar
• Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. 1999. Dependence of human stem cell engraftment, repopulation of NOD/SCID mice on CXCR4. Science. 283:845–848.
   PubMed Web of Science ®Google Scholar
• Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S, et al. 2007. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood. 109:1422–1432.
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Martin BJ. 2004. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 95:9–20.
   PubMed Web of Science ®Google Scholar
• Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. 2003. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 171:3426–3434.
   PubMed Web of Science ®Google Scholar
• Pountos I, Corscadden D, Emery P, Giannoudis PV. 2007. Mesenchymal stem cell tissue engineering: techniques for isolation, expansion and application. Injury. 38:S23–S33.
   PubMed Web of Science ®Google Scholar
• Prigione I, Benvenuto F, Bocca P, Battistini L, Uccelli A, Pistoia V. 2009. Reciprocal interactions between human mesenchymal stem cells and T cells or invariant natural killer T cells. Stem Cells. 27:693–702.
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, et al. 2008. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells26:151–162.
   PubMed Web of Science ®Google Scholar
• Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. 2007. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation. 83:71–76.
   PubMed Web of Science ®Google Scholar
• Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. 2003. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation. 76:1208–1213.
   PubMed Web of Science ®Google Scholar
• Ridger VC, Wagner BE, Wallace WA, Hellewell PG 2001. Differential effects of CD18, CD29, CD49 integrin subunit inhibition on neutrophil migration in pulmonary inflammation. J Immunol. 166:3484–3490.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E 1984. Fibronectin in cell adhesion, invasion. Cancer Metastasis Rev. 3:43–51.
   PubMed Web of Science ®Google Scholar
• Ryan JM, Barry FP, Murphy JM, Mahon BP. 2005. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2:8.
   PubMedGoogle Scholar
• Ryan JM, Barry F, Murphy JM, Mahon BP. 2007. Interferon does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 149: 353–363.
   PubMed Web of Science ®Google Scholar
• Rüster B, Göttig S, Ludwig RJ, Bistrian R, Müller S, Seifried E, et al. 2006. Mesenchymal stem cells display coordinated rolling, adhesion behavior on endothelial cells. Blood. 108:3938–3944.
   PubMed Web of Science ®Google Scholar
• Sackstein R 2005. The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr Opin Hematol. 12:444–450.
   PubMed Web of Science ®Google Scholar
• Sato K, Ozaki K, Mori M, Muroi K, Ozawa K 2010. Mesenchymal stromal cells for graft-versus-host disease: basic aspects and clinical outcomes. J Clin Exp Hematop. 50:79–89.
   PubMedGoogle Scholar
• Schwartz RE, Reyes M, Koodie L, Jiang Y, Blackstad M, Lund T, et al. 2002. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells.J Clin Invest. 109:1291–1302.
   PubMed Web of Science ®Google Scholar
• Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. 2008. Human leukocyte antigen G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte, natural killer function, to induce CD4 + CD25highFOXP3 + regulatory T cells. Stem Cells. 26:212–222.
   PubMed Web of Science ®Google Scholar
• Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R 2010. Mesenchymal stem cells for clinical application. Vox Sang. 98:93–107.
   PubMed Web of Science ®Google Scholar
• Shi M, Liu ZW, Wang FS. 2011. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol. 164:1–8.
   PubMed Web of Science ®Google Scholar
• Siegel G, Schäfer R, Dazzi F 2009. The immunosuppressive properties of mesenchymal stem cells. Transplantation87:S45–S49.
   PubMed Web of Science ®Google Scholar
• Sillence DO, Rimoin DL, Danks DM. 1978. Clinical variability in osteogenesis imperfecta-variable expressivity or genetic heterogeneity. Birth Defects Orig Artic Ser. 15:113–129.
   Google Scholar
• Simmons PJ, Torok-Storb B. 1991. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood. 78:55–62.
   PubMed Web of Science ®Google Scholar
• Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. 2006. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 24:74–85.
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. 2009. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood. 113:6576–6583.
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. 2008. Mesenchymal stem cells inhibit natural killer–cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood. 111:1327–1333.
   PubMed Web of Science ®Google Scholar
• Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. 2006. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 107:1484–1490.
   PubMed Web of Science ®Google Scholar
• Tolar J, Le Blanc K, Keating A, Blazar BR. 2010. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells. 28: 1446–1455.
   PubMed Web of Science ®Google Scholar
• Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. 2003. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 75:389–397.
   PubMed Web of Science ®Google Scholar
• Tursen U 2009. Activation markers in Behcet disease. Turkderm- Archives of the Turkish Dermatology, Venerology. 43:74–86.
   Web of Science ®Google Scholar
• Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C 2005. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol. 289:F31–FF42.
   PubMed Web of Science ®Google Scholar
• Türsen ÜPathophysiology of the Behçet’s Disease. Pathol Res Int. 2012: 2011.
   Google Scholar
• Urban VS, Kiss J, Kovacs J, Gocza E, Vas V, Monostori V, Uher F 2008. Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells. 26:244–253.
   PubMed Web of Science ®Google Scholar
• Valenick LV, Hsia HC, Schwarzbauer JE 2005. Fibronectin fragmentation promotes 4 1 integrin-mediated contraction of a fibrin– fibronectin provisional matrix. Exp Cell Res. 309:48–55.
   PubMed Web of Science ®Google Scholar
• Vija L, Farge D, Gautier J-F, Vexiau P, Dumitrache C, Bourgarit A, et al. 2009. Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes. Diabetes Metab. 35:85–93.
   PubMed Web of Science ®Google Scholar
• Vogel W, Grunebach F, Messam CA, Kanz L, Brugger W, Buhring HJ. 2003. Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. Haematologica88:126–133.
   PubMed Web of Science ®Google Scholar
• Volarevic V, Al-Qahtani A, Arsenijevic N, Pajovic S, Lukic ML 2009. Interleukin-1 receptor antagonist (IL-1Ra), IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity. 43:255–263.
   Web of Science ®Google Scholar
• Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. 2011. Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells. 29:5–10.
   PubMed Web of Science ®Google Scholar
• Wang M, Yang Y, Yang D, Luo F, Liang W, Guo S, Xu J. 2009. The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology. 126:220–232.
   PubMed Web of Science ®Google Scholar
• Waszak P, Alphonse R, Vadivel A, Ionescu L, Eaton F, Thébaud B 2012. Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats. Stem Cells Dev. 21:2789–2797.
   PubMed Web of Science ®Google Scholar
• Weil BR, Manukyan MC, Herrmann JL, Abarbanell AM, Poynter JA, Wang Y, Meldrum DR 2011. The immunomodulatory properties of mesenchymal stem cells: implications for surgical disease. J Surg Res. 167:78–86.
   PubMed Web of Science ®Google Scholar
• Werr J, Xie X, Hedqvist P, Ruoslahti E, Lindbom L 1998. 1 integrins are critically involved in neutrophil locomotion in extravascular tissue in vivo. J Exp Med. 187:2091–2096.
   PubMed Web of Science ®Google Scholar
• Woodside DG, Kram RM, Mitchell JS, Belsom T, Billard MJ, McIntyre BW, Vanderslice P 2006. Contrasting roles for domain 4 of VCAM-1 in the regulation of cell adhesion, soluble VCAM-1 binding to integrin 4 1. J Immunol. 176:5041–5049.
   PubMed Web of Science ®Google Scholar
• Xu G, Zhang Y, Zhang L, Ren G, Shi Y 2007. The role of IL-6 in inhibition of lymphocyte apoptosis by mesenchymal stem cells. Biochem Biophys Res Commun. 361:745–750.
   PubMed Web of Science ®Google Scholar
• Xu W, Zhang X, Qian H, Zhu W, Sun X, Hu J, et al. 2004. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood). 229:623–631.
   PubMed Web of Science ®Google Scholar
• Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, Yarmush ML. 2010. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant. 19:667.
   PubMed Web of Science ®Google Scholar
• Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al 2004. Effects of mesenchymal stem cells on differentiation, maturation, function of human monocyte-derived dendritic cells. Stem Cells Dev. 13:263–271.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li Y, Chen J, Cui Y, Lu M, Elias SB, et al. 2005. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol. 195:16–26.
   PubMed Web of Science ®Google Scholar
• Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. 2005. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 106:1755–1761.
   PubMed Web of Science ®Google Scholar